Progenics Pharmaceuticals to Present at the Cantor Fitzgerald 2017 Global Healthcare Conference
September 20 2017 - 8:30AM
Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company
developing innovative medicines and other products for targeting
and treating cancer, announced today that Mark R. Baker, Chief
Executive Officer, will present at the Cantor Fitzgerald 2017
Global Healthcare Conference in New York City on Wednesday,
September 27, 2017 at 11:30 a.m. Eastern Time.
A live webcast of the presentation will be
available in the Media Center of the Progenics
website, www.progenics.com. To ensure a timely connection,
users should register at least 15 minutes prior to the scheduled
start. An archive of the event will be available for 90 days.
About Progenics
Progenics develops innovative medicines and
other technologies to target and treat cancer. Progenics' pipeline
includes: 1) therapeutic agents designed to precisely target cancer
(AZEDRA® and 1095), 2) PSMA-targeted imaging agents for prostate
cancer (1404 and PyL™), and 3) imaging analysis tools. Progenics'
first commercial product, RELISTOR® (methylnaltrexone bromide) for
opioid induced constipation, is partnered with Valeant
Pharmaceuticals International, Inc.
This press release may contain projections and
other "forward-looking statements" regarding future events.
Statements contained in this communication that refer to Progenics'
estimated or anticipated future results or other non-historical
facts are forward-looking statements that reflect Progenics'
current perspective of existing trends and information as of the
date of this communication. Forward looking statements generally
will be accompanied by words such as "anticipate," "believe,"
"plan," "could," "should," "estimate," "expect," "forecast,"
"outlook," "guidance," "intend," "may," "might," "will,"
"possible," "potential," "predict," "project," or other similar
words, phrases or expressions. Such statements are predictions
only, and are subject to risks and uncertainties that could cause
actual events or results to differ materially. More information
concerning Progenics and such risks and uncertainties is available
on our website, and in our press releases and reports we file with
the U.S. Securities and Exchange Commission. Progenics is providing
the information in this press release only as of its date and,
except as expressly required by law, Progenics disclaims any intent
or obligation to update or revise any forward-looking statements,
whether as a result of new information, future events or
circumstances or otherwise.
Additional information concerning Progenics and
its business may be available in press releases or other public
announcements and public filings made after this release. For more
information, please visit www.progenics.com. Please follow us on
LinkedIn®. Information on or accessed through our website or social
media sites is not included in Progenics’ SEC filings.
(PGNX-F)
Contact:
Melissa DownsInvestor Relations(646)
975-2533mdowns@progenics.com
Progenics Pharmaceuticals (NASDAQ:PGNX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Progenics Pharmaceuticals (NASDAQ:PGNX)
Historical Stock Chart
From Sep 2023 to Sep 2024